|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 93 No. 8 (April 15), 1999:
pp. 2506-2514
Neutrophil Activation and Hemostatic Changes in Healthy Donors
Receiving Granulocyte Colony-Stimulating Factor
A. Falanga,
M. Marchetti,
V. Evangelista,
S. Manarini,
E. Oldani,
S. Giovanelli,
M. Galbusera,
C. Cerletti, and
T. Barbui
From the Hematology Division, Ospedali Riuniti, Bergamo, Italy; the
Istituto di Ricerche Farmacologiche Mario Negri Consorzio Mario Negri
Sud, S. Maria Imbaro, Italy; and NegriBergamo Laboratories, Bergamo,
Italy.
Granulocyte colony-stimulating factor (G-CSF) enhances neutrophil
functions in vitro and in vivo. It is known that neutrophil-derived products can alter the hemostatic balance. To understand whether polymorphonuclear leukocyte (PMN) activation, measured as PMN degranulation and phenotypical change, may be associated to hemostatic alterations in vivo, we have studied the effect of recombinant human
G-CSF (rHuG-CSF) administration on leukocyte parameters and hemostatic
variables in healthy donors of hematopoietic progenitor cells (HPCs).
Twenty-six consecutive healthy donors receiving 10 µg/kg/d rHuG-CSF
subcutaneously for 5 to 7 days to mobilize HPCs for allogeneic
transplants were included in the study. All of them responded to
rHuG-CSF with a significant white blood cell count increase. Blood
samples were drawn before therapy on days 2 and 5 and 1 week after
stopping rHuG-CSF treatment. The following parameters were evaluated:
(1) PMN activation parameters, ie, surface CD11b/CD18 antigen
expression, plasma elastase antigen levels and cellular elastase
activity; (2) plasma markers of endothelium activation, ie,
thrombomodulin (TM) and von Willebrand factor (vWF) antigens; (3)
plasma markers of blood coagulation activation, ie, F1+2, TAT
complex, D-dimer; and (4) mononuclear cell (MNC) procoagulant activity
(PCA) expression. The results show that, after starting rHuG-CSF, an in
vivo PMN activation occurred, as demonstrated by the significant
increment of surface CD11b/CD18 and plasma elastase antigen levels.
Moreover, PMN cellular elastase activity, which was significantly
increased at 1 day of treatment, returned to baseline at day 5 to 6, in
correspondence with the elastase antigen peak in the circulation. This
change was accompanied by a parallel significant increase in plasma
levels of the two endothelial and the three coagulation
markers. The PCA generated in vitro by unstimulated MNC
isolated from rHuG-CSF-treated subjects was not different from that of
control cells from untreated subjects. However, endotoxin-stimulated
MNC isolated from on-treatment individuals produced significantly more
PCA compared with both baseline and control samples. All of the
parameters were decreased or normal 1 week after stopping treatment.
These data show that rHuG-CSF induces PMN activation and transiently
affects some hemostatic variables in healthy HPC donor subjects. The
clinical significance of these findings remains to be established.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
E. N. Brown and J. D. Herrington
Review of the Relationship Between Venous Thromboembolism, Malignancy and Its Treatment
Journal of Pharmacy Practice,
April 1, 2008;
21(2):
126 - 137.
[Abstract]
[PDF]
|
|
|
|
|
|
|
P. Anderlini and R. E. Champlin
Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: recent findings and current challenges
Blood,
February 15, 2008;
111(4):
1767 - 1772.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. MENDEZ-FERRER and P. S. FRENETTE
Hematopoietic Stem Cell Trafficking: Regulated Adhesion and Attraction to Bone Marrow Microenvironment
Ann. N.Y. Acad. Sci.,
November 1, 2007;
1116(1):
392 - 413.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M R Ray, S Mukherjee, S Roychoudhury, P Bhattacharya, M Banerjee, S Siddique, S Chakraborty, and T Lahiri
Platelet activation, upregulation of CD11b/CD18 expression on leukocytes and increase in circulating leukocyte-platelet aggregates in Indian women chronically exposed to biomass smoke
Human and Experimental Toxicology,
November 1, 2006;
25(11):
627 - 635.
[Abstract]
[PDF]
|
|
|
|
|
|
|
I. Ben-Dor, S. Fuchs, and R. Kornowski
Potential Hazards and Technical Considerations Associated With Myocardial Cell Transplantation Protocols for Ischemic Myocardial Syndrome
J. Am. Coll. Cardiol.,
October 17, 2006;
48(8):
1519 - 1526.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Passamonti, E. Rumi, D. Pietra, M. G. D. Porta, E. Boveri, C. Pascutto, L. Vanelli, L. Arcaini, S. Burcheri, L. Malcovati, et al.
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders
Blood,
May 1, 2006;
107(9):
3676 - 3682.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Sainz and M. Sata
Targeting bone marrow to treat vascular diseases: Accelerated vascular healing by colony stimulating factor
Cardiovasc Res,
April 1, 2006;
70(1):
3 - 5.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Valgimigli, G. M. Rigolin, C. Cittanti, P. Malagutti, S. Curello, G. Percoco, A. M. Bugli, M. D. Porta, L. Z. Bragotti, L. Ansani, et al.
Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile
Eur. Heart J.,
September 2, 2005;
26(18):
1838 - 1845.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Balabanian, B. Lagane, J. L. Pablos, L. Laurent, T. Planchenault, O. Verola, C. Lebbe, D. Kerob, A. Dupuy, O. Hermine, et al.
WHIM syndromes with different genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12
Blood,
March 15, 2005;
105(6):
2449 - 2457.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. D. Garlichs, S. Eskafi, I. Cicha, A. Schmeisser, B. Walzog, D. Raaz, C. Stumpf, A. Yilmaz, J. Bremer, J. Ludwig, et al.
Delay of neutrophil apoptosis in acute coronary syndromes
J. Leukoc. Biol.,
May 1, 2004;
75(5):
828 - 835.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. El Ouriaghli, H. Fujiwara, J. J. Melenhorst, G. Sconocchia, N. Hensel, and A. J. Barrett
Neutrophil elastase enzymatically antagonizes the in vitro action of G-CSF: implications for the regulation of granulopoiesis
Blood,
March 1, 2003;
101(5):
1752 - 1758.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Valenzuela-Fernandez, T. Planchenault, F. Baleux, I. Staropoli, K. Le-Barillec, D. Leduc, T. Delaunay, F. Lazarini, J.-L. Virelizier, M. Chignard, et al.
Leukocyte Elastase Negatively Regulates Stromal Cell-derived Factor-1 (SDF-1)/CXCR4 Binding and Functions by Amino-terminal Processing of SDF-1 and CXCR4
J. Biol. Chem.,
May 3, 2002;
277(18):
15677 - 15689.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-P. Levesque, Y. Takamatsu, S. K. Nilsson, D. N. Haylock, and P. J. Simmons
Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor
Blood,
September 1, 2001;
98(5):
1289 - 1297.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Falanga, M. Marchetti, V. Evangelista, A. Vignoli, M. Licini, M. Balicco, S. Manarini, G. Finazzi, C. Cerletti, and T. Barbui
Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera
Blood,
December 15, 2000;
96(13):
4261 - 4266.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
